Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
The purpose of this study is to determine the safety and recommended dose of AIC100 for treating patients with advanced thyroid cancer or anaplastic thyroid cancer, and to understand the side effects that participants with your disease may have when they are treated with AIC100. There are limited treatment options available for people with these diseases.
AIC100 is a Chimeric Antigen Receptor (CAR) T-cell product. This treatment uses your own immune cells, called T cells. T cells fight infections and in some cases, can also kill cancer cells. Currently, your T cells are not able to kill your cancer cells. CAR T-cell products are genetically modified T-cells that can recognize and possibly kill cancer cells.
AIC100 is an investigational treatment. “Investigational” means that it is an experimental therapy that has not yet been approved by the United States Food and Drug Administration (FDA).
Inclusion Criteria:
Exclusion Criteria
Detailed eligibility will be reviewed when you contact the study team.